Cooperative Agreement U01FD008720
Award Date 9/22/25
Completion Date 8/31/28
Dollars Obligated $3M
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
- Federal Cooperative Agreement Summary The University of Texas MD Anderson Cancer Center received a $1.5M Cooperative Agreement from the Food and Drug Administration (FDA) Research program (CFDA 93.103) awarded September 22, 2025, with completion targeted for August 31, 2028. This award funds research investigating metabolomic and genetic factors that decouple immune checkpoint inhibitor (ICI) tumor efficacy from cardiovascular toxicity. The project addresses a critical clinical gap: while ICIs...
- Federal Cooperative Agreement Summary The Food and Drug Administration (FDA) Research program (CFDA 93.103) awarded the Regents of the University of Minnesota a Cooperative Agreement valued at $199,999 on September 20, 2025, to advance antimicrobial use (AU) measurement in U.S. companion animal veterinary practice through September 2030. The project leverages the Companion Animal Veterinary Surveillance Network (CAVSNET), a public-private partnership that standardizes prescribing data from...
- Federal Cooperative Agreement Summary Cornell University received a $200,000 Cooperative Agreement from the Food and Drug Administration (FDA) Center for Veterinary Medicine under the FDA Research program (CFDA 93.103), awarded September 20, 2025, with a completion date of August 31, 2030. The project develops artificial intelligence (AI) and dashboard tools to collect, anonymize, and summarize companion animal antimicrobial use (AMU) data. The primary deliverable is a large language model (LLM)...
- Federal Cooperative Agreement Summary Duke University's Office of Research Administration received a $565,250 Cooperative Agreement awarded on August 6, 2025, by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The agreement, with completion scheduled for July 31, 2030, supports the development and validation of serum pro-N-cadherin (PNC) as an early biomarker for identifying radiation-induced heart disease in acute...
- Federal Cooperative Agreement Summary Massachusetts General Hospital received a $100,000 cooperative agreement awarded September 2, 2025, through the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) to develop machine learning and artificial intelligence (AI) tools for predicting disease manifestation in individuals with pathogenic genetic variants. The project, titled "PRISM: Ethically-Guided Multimodal AI Models for...
- Federal Cooperative Agreement Summary Abstractive Health, Inc. received a $1.25 million Small Business Innovation Research (SBIR) Phase II Cooperative Agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), effective July 1, 2025, through June 30, 2027. The awardee will develop and refine a machine learning-enabled software tool that leverages natural language processing (NLP) to automatically generate clinically relevant...
- Federal Cooperative Agreement Summary Harvard Medical School received a $1.22 million Cooperative Agreement from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025, through September 26, 2025. The award funds research to optimize preanalytical tumor handling conditions for Ramp Up Dynamic BH3 Profiling (RUDBP), a functional precision medicine biomarker designed to identify ideal therapies for individual ovarian cancer patients. The...
- Federal Cooperative Agreement Award Summary Northern Michigan University is leading a collaborative research initiative funded by the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) to validate D2HGLO, a novel diagnostic and predictive tool for detecting D-2-hydroxyglutarate (D-2-HG), an oncometabolite associated with mutant isocitrate dehydrogenase (IDH) gliomas. This $194,787 cooperative agreement, awarded September 18, 2025, with completion by...
- Federal Cooperative Agreement Award Summary The University of Michigan's Regents, through its Office of Research and Sponsored Projects, received a $210,600 Cooperative Agreement from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective September 1, 2025, through August 31, 2027. This award supports the analytical and clinical validation of an H3K27M circulating tumor DNA (ctDNA) assay for diffuse midline glioma (DMG) surveillance. The...
- Federal Cooperative Agreement Summary Health Research, Inc.'s Wadsworth Center Division has been awarded $480,000 under a Cooperative Agreement with the Food and Drug Administration (FDA) Research program (CFDA 93.103), effective September 25, 2025, through June 30, 2030. This award supports the continuation of an integrated food defense testing and method development program serving the FDA's Food Emergency Response Network (FERN). The Wadsworth Center will provide radiochemical,...